Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On February 10, Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy ...

Roivant Sciences (NASDAQ:ROIV) is gearing up to announce its quarterly earnings on Friday, 2026-02-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Analysts' ratings for Roivant Sciences (NASDAQ:ROIV) over the last quarter vary from bullish to bearish, as provided by 4 analysts. Summarizing their recent assessments, the table below illustrates ...

(RTTNews) - Shares of Roivant Sciences Ltd. (ROIV) are climbing about 17 percent on Friday morning trading over the announcement of positive results from the Phase 2 study of brepocitinib in cutaneous ...

Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2025 Earnings Call Transcript February 6, 2026 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is $-0.00038, expectations were $-0.27. Operator: ...

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.13 per share a year ago. These ...

Roivant Sciences is upgraded to Buy after strong Phase 2 BEACON data for brepocitinib in cutaneous sarcoidosis, highlighting blockbuster potential. Brepocitinib's once-daily oral profile and robust ...

Rashes and lesions caused by cutaneous sarcoidosis can cover much of the body, sometimes becoming disfiguring. There are no FDA-approved treatments for this rare disease, which has been overlooked by ...

Shares of Roivant Sciences were higher after the company released positive results from a phase-two study of its brepocitinib treatment for cutaneous sarcoidosis, a skin disease. The stock rose 14% to ...

Roivant saw its share prices jump by 19.4 percent week-on-week, hitting a new all-time high, as investors snapped up shares following encouraging results from its pipeline projects, with one already ...